Related references
Note: Only part of the references are listed.Frailty in Nonalcoholic Fatty Liver Cirrhosis: A Comparison with Alcoholic Cirrhosis, Risk Patterns, and Impact on Prognosis
Lubomir Skladany et al.
CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2021)
Pasta Consumption and Connected Dietary Habits: Associations with Glucose Control, Adiposity Measures, and Cardiovascular Risk Factors in People with Type 2 Diabetes-TOSCA.IT Study
Marilena Vitale et al.
NUTRIENTS (2020)
NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications
Giovanni Targher et al.
GUT (2020)
Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts
Myriam Alexander et al.
BMC MEDICINE (2019)
A novel specific peroxisome proliferator-activated receptor γ (PPARγ) modulator YR4-42 ameliorates hyperglycaemia and dyslipidaemia and hepatic steatosis in diet-induced obese mice
Yi Huan et al.
DIABETES OBESITY & METABOLISM (2019)
The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis
Zobair M. Younossi et al.
JOURNAL OF HEPATOLOGY (2019)
From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
Amalia Gastaldelli et al.
JHEP REPORTS (2019)
Nonalcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: A Meta-analysis
Alessandro Mantovani et al.
DIABETES CARE (2018)
Risk of heart failure in diabetic patients receiving sulfonylureas
Olga Vaccaro et al.
EUROPEAN JOURNAL OF HEART FAILURE (2018)
Pioglitazone Attenuates Palmitate-Induced Inflammation and Endoplasmic Reticulum Stress in Pancreatic β-Cells
Seok-Woo Hong et al.
ENDOCRINOLOGY AND METABOLISM (2018)
Comment to: EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
Jorge Fonseca et al.
JOURNAL OF HEPATOLOGY (2017)
Isocaloric Dietary Changes and Non-Alcoholic Fatty Liver Disease in High Cardiometabolic Risk Individuals
Giuseppe Della Pepa et al.
NUTRIENTS (2017)
Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA. IT): a randomised, multicentre trial
Olga Vaccaro et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Pioglitazone and the Risk of Bladder Cancer: A Meta-Analysis
Elena Filipova et al.
DIABETES THERAPY (2017)
Pioglitazone and the Risk of Bladder Cancer: A Meta-Analysis
Elena Filipova et al.
DIABETES THERAPY (2017)
Liver biopsy in type 2 diabetes mellitus: Steatohepatitis represents the sole feature of liver damage
Mario Masarone et al.
PLOS ONE (2017)
Role of Adipose Tissue Insulin Resistance in the Natural History of Type 2 Diabetes: Results From the San Antonio Metabolism Study
Amalia Gastaldelli et al.
DIABETES (2017)
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus A Randomized Trial
Kenneth Cusi et al.
ANNALS OF INTERNAL MEDICINE (2016)
Pioglitazone for advanced fibrosis in nonalcoholic steatohepatitis: New evidence, new challenges
Giovanni Musso et al.
HEPATOLOGY (2016)
Nonalcoholic Fatty Liver Disease A Systematic Review
Mary E. Rinella
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels
Paola Portillo-Sanchez et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Can a Selective PPARγ Modulator Improve Glycemic Control in Patients With Type 2 Diabetes With Fewer Side Effects Compared With Pioglitazone?
Alex M. DePaoli et al.
DIABETES CARE (2014)
A single non-invasive model to diagnose non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)
Munkhzul Otgonsuren et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2014)
The Future of Thiazolidinedione Therapy in the Management of Type 2 Diabetes Mellitus
Hanford Yau et al.
CURRENT DIABETES REPORTS (2013)
Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: Impact on cardiovascular events. A randomized controlled trial
O. Vaccaro et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2012)
Pioglitazone improvement of fasting and postprandial hyperglycaemia in Mexican-American patients with Type 2 diabetes: a double tracer OGTT study
Leonard C. Glass et al.
CLINICAL ENDOCRINOLOGY (2010)
Visceral Adiposity Index A reliable indicator of visceral fat function associated with cardiometabolic risk
Marco C. Amato et al.
DIABETES CARE (2010)
Hepatic steatosis index: A simple screening tool reflecting nonalcoholic fatty liver disease
Jeong-Hoon Lee et al.
DIGESTIVE AND LIVER DISEASE (2010)
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis.
Arun J. Sanyal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Prediction of Non-Alcoholic Fatty Liver Disease and Liver Fat Using Metabolic and Genetic Factors
Anna Kotronen et al.
GASTROENTEROLOGY (2009)
Importance of Changes in Adipose Tissue Insulin Resistance to Histological Response During Thiazolidinedione Treatment of Patients with Nonalcoholic Steatohepatitis
Amalia Gastaldelli et al.
HEPATOLOGY (2009)
Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis
Guruprasad P. Aithal et al.
GASTROENTEROLOGY (2008)
Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis
Bogdan Balas et al.
JOURNAL OF HEPATOLOGY (2007)
Reduction in hematocrit and hemoglobin following pioglitazone treatment is not hemodilutional in type II diabetes mellitus
R. Berria et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Renata Belfort et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
The effect of pioglitazone on the liver - Role of adiponectin
Amalia Gastaldelli et al.
DIABETES CARE (2006)
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial
JA Dormandy et al.
LANCET (2005)
Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes
Y Miyazaki et al.
DIABETES CARE (2002)
Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes - A 6-month randomized placebo-controlled dose-response study
S Aronoff et al.
DIABETES CARE (2000)
Share Paper
